InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Explore the complete record of transactions filed by LYONS GARY A, Director. Director active across 4 companies, notably Travere Therapeutics, Inc.. Cumulatively, 11 reports have been published. Total volume traded: €2.6m. The latest transaction was disclosed on 20 May 2022 — Attribution. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations11 total
025,000 shares0
Common Stock
SEC:0001140361-22-020305:0·
03,000 shares0
Common Stock
SEC:0001209191-22-028694:0·
€93,24115,000 shares@ €6.2160.0007% mcap3.5% of flow
Common Stock
SEC:0001209191-22-025824:0·
€454,4165,000 shares@ €90.88310.0032% mcap35.6% of flow
Common Stock
SEC:0001209191-21-060283·
€454,4165,000 shares@ €90.88310.0032% mcap17.2% of flow
Common Stock
SEC:0001209191-21-060283:0·
€823,77310,000 shares@ €82.37730.0058% mcap64.4% of flow
Common Stock
SEC:0001209191-21-040445·
€823,77310,000 shares@ €82.37730.0058% mcap31.1% of flow
Common Stock
SEC:0001209191-21-040445:0·
025,000 shares0
Common Stock
SEC:0001179110-21-005765·
025,000 shares0
Common Stock
SEC:0001179110-21-005765:0·
03,000 shares0
Common Stock
SEC:0001209191-21-033852·
03,000 shares0
Common Stock
SEC:0001209191-21-033852:0·
11 of 11 declarations
About LYONS GARY A
Gary A. Lyons is a Director at Travere Therapeutics, Inc. and RIGEL PHARMACEUTICALS INC. In these roles, he contributes to the governance and strategy of the companies. His expertise in the pharmaceutical sector is essential for their development.
